Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Tiagabine, sold under the brand name Gabitril, is an anticonvulsant medication which is used in the treatment of epilepsy. It is also used off-label in the treatment of insomnia and anxiety disorders. However, off-label use is discouraged as the drug has been associated with new-onset seizures in people without epilepsy. Tiagabine is taken orally.
Read the full article on WikipediaFocal onset seizures Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The condition must have failed to be controlled satisfactorily by at least one other antiseizure medication. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Tiagabine acts a selective GABA transporter 1 (GAT-1) blocker and hence as a GABA reuptake inhibitor (GRI). The GAT-1 is one of at least four distinct GABA transporters (GATs), with the GAT-1 being the predominant subtype in the brain, accounting for 85% of GATs in this part of the body, and thought to be responsible for most γ-aminobutyric acid (GABA) reuptake in synapses. The drug has more than 1,000-fold selectivity for the GAT-1 over the GABA transporter 2 (GAT-2), GABA transporter 3 (GAT-3), and betaine/GABA transporter (BGT-1; GAT-4). It also shows no significant affinity for GABA receptors or numerous other targets. In addition, it does not affect key cardiac ion channels. Through GAT-1 blockade, tiagabine increases levels of GABA, the major inhibitory neurotransmitter in the central nervous system, and consequently increases GABA receptor activation and GABAergic signaling, including of both GABAA and GABAB receptors. The drug has been found to increase GABAergic signaling in the hippocampus, globus pallidus, ventral pallidum, and substantia nigra in animals. It produces anticonvulsant, neuroprotective, hypnotic, analgesic, and anxiolytic-like effects in animals.”
“4.5–9.0 hoursEnzyme-induced patients: 2–3 hours”
Working under the parallel aged-care framework? Aged-care equivalent →